Par Announces Strategic Alliance With MN Pharmaceuticals
作者: 整理时间:2005-10-27
10/24/2005
Spring Valley, NY -- Par Pharmaceutical
Companies, Inc. announced that it has entered into an
agreement with MN Pharmaceuticals, based in Istanbul, Turkey, to develop and
market generic versions of injectable pharmaceuticals. The companies will
collaborate on the development of as many as 10 generic injectable drugs.
"We are very pleased to enter into this partnership with MN
Pharmaceuticals," said Scott Tarriff, president and chief executive officer.
"MN is one of Turkey's leading and oldest pharmaceutical companies, and is
widely respected within the global pharmaceutical community. This
collaboration permits Par to enter a new market segment, generic injectables,
in a cost effective way."
Under the terms of the agreement, MN will be responsible for the
development and manufacture of all products. Par will provide regulatory
affairs support and submit each Abbreviated New Drug Application (ANDA) to the
U.S. Food and Drug Administration as the U.S. filing agent on behalf of MN.
Par will be responsible for any litigation expenses arising from the ANDA
submissions. Par will have exclusive rights to market, sell and distribute
the products in the U.S. Par and MN will share the net profits generated by
all marketed products.
SOURCE: MN Pharmaceuticals
|
